Evidence map›Paper›PMID 26495806›Full record

ArticleCancer science2016

Monitoring and evaluating the quality of cancer care in Japan using administrative claims data.

Momoko Iwamoto, Fumiaki Nakamura, Takahiro Higashi

Abstract read
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Consultations of patients with cancer to enhance shared decision-making in Japan: A retrospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
  7. Article
  8. Article
  9. Observational
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  15. Article
  16. First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan.International journal of environmental research and public health · 2021
    Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Momoko IwamotoDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Fumiaki NakamuraDepartment of Public Health/Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takahiro HigashiDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The importance of measuring the quality of cancer care has been well recognized in many developed countries, but has never been successfully implemented on a national level in Japan. We sought to establish a wide-scale quality monitoring and evaluation program for cancer by measuring 13 process-of-care quality indicators (QI) using a registry-linked claims database. We measured two QI on pre-treatment testing, nine on adherence to clinical guidelines on therapeutic treatments, and two on supportive care, for breast, prostate, colorectal, stomach, lung, liver and cervical cancer patients who were diagnosed in 2011 from 178 hospitals. We further assessed the reasons for non-adherence for patients who did not receive the indicated care in 26 hospitals. QI for pretreatment testing were high in most hospitals (above 80%), but scores on adjuvant radiation and chemoradiation therapies were low (20-37%), except for breast cancer (74%). QI for adjuvant chemotherapy and supportive care were more widely distributed across hospitals (45-68%). Further analysis in 26 hospitals showed that most of the patients who did not receive adjuvant chemotherapy had clinically valid reasons for not receiving the specified care (above 70%), but the majority of the patients did not have sufficient reasons for not receiving adjuvant radiotherapy (52-69%) and supportive care (above 80%). We present here the first wide-scale quality measurement initiative of cancer patients in Japan. Patients without clinically valid reasons for non-adherence should be examined further in future to improve care.

Indexed as

Quality Indicators, Health CareGuideline AdherenceHumansJapanNeoplasmsRegistriesInsurance claim reportingManagement and analysis of medical dataOncology ServiceQuality indicatorsQuality of health care

Identifiers

PMID26495806
PMCPMC4724820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.